Highest-materiality recent filing
Net loss $45.5M ($0.32/sh) vs $39.9M ($0.36/sh) YoY; R&D $33.5M, G&A $15.2M.
CFO Daniella Beckman ceased serving as principal financial officer effective April 15, 2026.
Tango Therapeutics appoints new CFO, additional execs to accelerate vopimetostat development
Daniella Beckman departs as CFO effective April 15; Matthew Gall named successor.
Net loss $38.7M for Q4 2025 ($0.29/share) vs $30.8M for Q4 2024; FY2025 net loss $101.6M vs $130.3M.
Barbara Weber, M.D. retires as President and CEO effective Jan 8, 2026; becomes Executive Chair through 2026.
Net income $15.9M ($0.14 basic EPS) vs net loss $29.2M in Q3 2024; nine-month net loss $62.8M.
Tango Therapeutics raises ~$212M via registered direct offering and PIPE
Registered direct offering of 21.0M shares and 3.2M pre-funded warrants at $8.66; net proceeds ~$197M.
Tango Therapeutics Q2 net loss $38.9M ($0.35/sh); Gilead collab truncated
Net loss $38.9M ($0.35 per share) vs $25.6M ($0.24) in Q2 2024; revenue fell to $3.2M.
Tango Therapeutics Q1 net loss $39.9M; cash runway extended to Q1 2027; TNG462 data update 2H2025
Net loss of $39.9M ($0.36/share) for Q1 2025 vs $37.9M ($0.35/share) in Q1 2024.
Tango Therapeutics reports Q4 2024 net loss of $37.7M; cash runway into 3Q 2026
Net loss of $37.7M for Q4 2024 ($0.35 per share) vs $30.8M loss in Q4 2023; full year net loss $130.3M ($1.19 per share).
Tango reports Q3 loss $29.2M; TNG462 shows durable activity; PRMT5 program advanced
TNG462 demonstrated clinical activity across multiple tumor types; 43% ORR in cholangiocarcinoma (n=7); median time on treatment 24 weeks and increasing.
Tango Therapeutics discontinues TNG348 program due to liver toxicity in phase 1/2 trial
Phase 1/2 trial of TNG348, a USP1 inhibitor, terminated because of Grade 3/4 liver function abnormalities in patients on study >8 weeks.
Tango Therapeutics Q1 2024 net loss $37.9M ($0.35/sh); cash $343.6M funds into late 2026
Net loss of $37.9M, or $0.35 per share, vs $28.0M ($0.32) in Q1 2023.
Tango Therapeutics Q4 2023 net loss $30.8M; cash $336.9M; pipeline advances
Net loss Q4 2023 $30.8M ($0.32/sh); full year net loss $101.7M ($1.08/sh).
Also on May 12, 2026, Kanishka Pothula resigned from the Board and as a member of the Nominating and Corporate Governance Committee of the Board (the “NCG Committee”), in each case effective as of May 13, 2026.
the Board appointed Sung Lee as Lead Independent Director of the Board and the Chairperson of the Compensation Committee and as a member thereof, each effective as of May 13, 2026.
On May 12, 2026, Alexis Borisy resigned from the Company’s Board of Directors (the “Board”), as Lead Independent Director of the Board, and as the Chairperson of the Compensation Committee of the Board (the “Compensation Committee”) and as a member thereof, in each case effective as of May 13, 2026.
on April 10, 2026, the board of directors (the “Board”) of Tango Therapeutics, Inc. (the “Company”) determined that Daniella Beckman will no longer serve as the Company’s Chief Financial Officer, principal accounting officer and principal financial officer, effective as of April 15, 2026.
Max materiality 0.80 · Median 0.60 · Most common event earnings